Condition
Crohn's disease news across medications, symptoms, tests, procedures, complications, research, access, and daily life.
Page 16 of 18 · 826 articles
This article is a market research summary about the global Crohn’s disease treatment market — it describes sales forecasts, industry players, and market trends rather than new clinical findings or patient-focused...
A study aiming to identify who is likely to develop Crohn’s disease and to test preventing it could eventually allow truly early treatment before symptoms begin. If successful, validated biomarkers and a risk score could...
Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Irritable bowel syndrome, and Fatigue. The original article is from springermedicine.com.
People with Crohn’s often look for complementary options to help symptoms. This article summarizes what limited research exists on several essential oils and plant extracts so readers can weigh potential benefits and...
Cure8 could only read part of this source from patientcareonline.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Biomarker.
Researchers are trying to find blood biomarkers and a risk score that could predict who will develop Crohn’s disease before symptoms appear, which might enable earlier interventions or prevention in the future.
People with celiac disease may have higher risks for several digestive cancers and for inflammatory bowel diseases (Crohn’s and UC) according to this large French cohort study. Knowing these associations can help...
If successful, validated biomarkers and a blood risk score could allow clinicians to identify people at high risk of developing Crohn's disease and eventually test interventions to prevent symptoms. Prevention-focused...
This project aims to detect Crohn’s before symptoms appear and test preventive treatment—research that could change diagnosis and care for people with family risk. Successful biomarkers could allow earlier monitoring or...
The article reports that many people with IBD face unaffordable care and medication access problems that can lead to nonadherence and worse health. It offers practical steps to manage costs now and calls for policy...
Anal fistulas are a common and often painful complication of Crohn’s disease that usually need medical or surgical treatment. Managing the underlying Crohn’s with biologic therapy is often necessary for fistulas to heal....
The study suggests a possible link between psoriasis, leaky gut, and Crohn’s disease—topics that could help explain why some people with psoriasis report more gut problems. People with psoriasis or IBD may find the...
This study links a specific SERPINB4 gene mutation to impaired intestinal epithelial cell function in twins with Crohn’s disease, which could help explain how rare genetic variants contribute to disease in some patients.
This gives adults with moderately to severely active Crohn’s disease another FDA‑approved biologic option, including for people who did not respond to or could not tolerate other therapies.
Personal stories can help others with Crohn’s feel less alone and learn about the emotional and practical impacts of the disease on daily life and professional athletes. It highlights how online communities may provide...
Cure8 found this source from expressandstar.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Community and awareness. Open the original article for the...
Based on the title and source metadata, this appears to be a fda approval related to Crohn's disease, Inflammatory bowel disease, and Medications. The original article is from msn.com.
Cure8 could only read part of this source from hcplive.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Mirikizumab.
Based on the title and source metadata, this appears to be a case report related to Crohn's disease and Complications. The original article is from cureus.com.
A new FDA approval expands treatment options for adults with moderate-to-severe Crohn's disease and means mirikizumab (Omvoh) is now approved for both Crohn's disease and ulcerative colitis. The decision was based on...
Based on the title and source metadata, this appears to be a fda approval related to Crohn's disease, Mirikizumab, and IL-23 inhibitor. The original article is from gastroendonews.com.
Understanding the differences between Crohn’s and ulcerative colitis helps patients and caregivers recognize likely symptom patterns, know which tests and treatments are commonly used, and when to seek specialist care....
Cure8 found this source from hmpgloballearningnetwork.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Mirikizumab. Open the original article for the...
Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Ulcerative colitis, and Inflammatory bowel disease. The original article is from msn.com.
Cure8 could only read part of this source from managedhealthcareexecutive.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and...
Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Mirikizumab. The original article is from msn.com.
This approval adds a newly authorized biologic option (mirikizumab/Omvoh) for adults with moderate-to-severe Crohn disease, including people who have not done well on steroids, immunomodulators, or prior biologics.
Cure8 found this source from marketscreener.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Medications. Open the original article for the full details.
Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Medications. Open the original article for the full details.
Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Medications. The original article is from webmd.com.
A new FDA approval means another biologic option for people with moderately to severely active Crohn’s disease, including patients who have failed or not tolerated prior therapies.
This announces a new FDA‑approved treatment (mirikizumab/Omvoh) for adults with moderately to severely active Crohn disease, offering another option for people who haven’t responded to prior therapies. The approval was...
A new FDA-approved biologic (Omvoh/mirikizumab) gives adults with moderate-to-severe Crohn disease another treatment option with one-year trial data showing improved clinical remission and endoscopic healing versus...
Based on the title and source metadata, this appears to be a market or business news related to Crohn's disease, Inflammatory bowel disease, and Access, cost, and policy. The original article is from...
An FDA approval means another biologic option is available for Crohn’s disease, which could affect treatment choices and insurance coverage. The approval also signals pharma competition and pipeline activity that may...
An FDA approval means Omvoh is now an available biologic option for adults with Crohn’s disease, potentially expanding treatment choices. Payer decisions mentioned in the article could affect how quickly patients can...
This gives adults with moderately to severely active Crohn’s disease an additional FDA-approved biologic option that targets the IL-23 pathway. Approval was supported by late-stage trial results showing improvements in...
A new FDA-approved treatment option is now available for adults with moderately to severely active Crohn’s disease, including people who’ve not responded to or tolerated prior therapies. Approval was supported by phase 3...
A new FDA-approved biologic option (Omvoh/mirikizumab) is now available for adults with moderately to severely active Crohn’s disease, potentially expanding treatment choices.
A new FDA approval means another IL-23 option is formally available for people with moderately to severely active Crohn’s disease, including patients whose disease did not respond to other therapies. This could affect...
This provides a new FDA‑approved biologic option (mirikizumab/Omvoh) for adults with moderate–severe Crohn's disease, including people who did not respond to prior therapies. The approval was based on Phase 3 trial...
FDA approval means mirikizumab (Omvoh) is now an available biologic option in the US for adults with moderately to severely active Crohn’s disease, especially for people who did not respond to standard treatments. It may...
People with Crohn’s disease may be affected by the market trends that influence drug availability, costs, and development of new monitoring tools. Emerging monitoring technology could change how flare-ups are detected...
Cure8 found this source from markets.businessinsider.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Mirikizumab. Open the original article for the full...
Cure8 could only read part of this source from gurufocus.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Mirikizumab.
A newly FDA-approved biologic (Omvoh/mirikizumab) gives adults with moderately to severely active Crohn's disease another targeted treatment option. It's the same IL-23–targeting drug already approved for ulcerative...
A new FDA approval means an additional biologic treatment option for adults with moderate to severe Crohn's disease. This may affect treatment choices and insurance coverage discussions for people with IBD.
Cure8 could only read part of this source from patientcareonline.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Mirikizumab.
